INTRODUCTION
Platinum-based anticancer agents are among the most widely used agents in clinical oncology. 1, 2 Nucleotide excision repair (NER) is the pathway through which platinum --DNA damage is repaired; and, ERCC1 is a useful biomarker for the NER process in human cells. 3 --5 Understanding the molecular and pharmacological control of NER may allow for a more complete understanding of the modes of cellular and clinical resistance to this class of agents. In addition, such information may contribute to the development of non-platinum agents that damage DNA and/or modulate DNA repair.
More than 30 genes are involved in the NER process, which goes from DNA damage recognition, through incision into the DNA strand at sites flanking the DNA damage, through the helicase functions of XPB and XPD, through damage removal, and through gap-filling and ligation. 6, 7 DNA damage excision is rate limiting to the process. In DNA damage excision, the last sub-step is the 5 0 incision into the DNA strand, relative to the site of covalent damage. This 5 0 incision occurs after the 3 0 incision, and after the 3 0 -45 0 and 5 0 -43 0 helicase functions of XPB and XPD. The 5 0 incision is executed by the ERCC1 --XPF heterodimer. Previous publications from our group show that upregulation of ERCC1 is necessary for the repair of platinum --DNA damage after an acute exposure to cisplatin. 8 --10 ERCC1 is inducible in human cells. 8 In human ovarian cancer cells, ERCC1 is upregulated after a 1-h treatment with cisplatin. However, a series of events precede the upregulation of ERCC1. 8, 11 After a 1-h cisplatin IC50 (half maximal inhibitory concentration) dose, A2780-CP70 human ovarian cancer cells upregulate the mRNA and protein of c-jun and c-fos. The peak in mRNA levels occurs at 1 --2 h. C-Jun protein is then upregulated, and peaks at 3 --5 h after cisplatin. C-Jun protein has to be phosphorylated to be activated. C-Jun phosphorylation is greatly enhanced at 1 h after cisplatin treatment, and peaks at 15-fold over baseline 3 --5 h after cisplatin treatment. C-jun phosphorylation at sites Ser63/73 is necessary to activate AP1. AP1 activation leads to increased transcription of ERCC1.
Laner-Plamberger et al. 12 reported their findings of the molecular interface between Gli and c-jun in immortalized keratinocytes. They report that c-jun has five potential Gli binding sites in the promoter of the c-jun gene. Further, there are two c-jun binding sites in the promoter of the c-jun gene. The five Gli binding sites are close together, approximately À1000 to À700 in the promoter, relative to the transcription start site. The two c-jun binding sites are approximately 200 --300 bases further downstream on the promoter, closer to the initiation codon.
According to their studies, Gli1 upregulates c-jun through one specific binding site, but this also requires activated c-jun protein in their in vitro system. 12 Further, Gli2 can upregulate c-jun through that same specific binding site. When Gli2 and c-jun bind to their respective sites concurrently, there is synergistic upregulation of c-jun. When Gli1 and c-jun bind to the same respective sites in the promoter, synergistic upregulation is not seen. They conclude that Gli1 and Gli2 are positive transcriptional regulators for c-jun, and that c-jun is a positive transcriptional regulator for itself. In the studies we present, we assess human ovarian cancer cells for a possible relationship between Gli1, c-jun and cellular resistance to cisplatin.
Our group reported on the relationship between c-jun, AP1 and ERCC1. 8, 11 Laner-Plamberger et al. 12 reported on the relationship between Gli and c-jun. In this report, we investigate the possible relationship between Gli, c-jun, ERCC1 and cellular resistance to cisplatin.
RESULTS
We assessed the effects of an IC50 dose of anti-Gli1 shRNA on cisplatin-sensitive A2780 cells and cisplatin-resistant A2780-CP70 cells. The IC50 dose of anti-Gli1 shRNA for these cells is 2 mg/ml shRNA per 200 ml well. These results are shown in Figure 1 , panels a, b, c and d. In panels a and b, the two cell lines are compared for the effects on the protein levels of Gli1, Gli2 and c-jun. GAPDH protein is used as the control. In cisplatin-sensitive A2780 cells, there was no apparent effect on Gli1 or Gli2 protein levels. C-jun protein may have increased slightly under these conditions. In cisplatin-resistant A2780-CP70 cells, Gli1 protein was reduced by a factor of 10, after 24 h of anti-Gli1 shRNA. Gli2 levels may have increased slightly. Total c-jun protein level was essentially unchanged, correcting for the GAPDH control.
In Figure 1 , panels c and d, these two cell lines are compared for the proteins Shh and Ihh, before and after 24 h of anti-Gli1 shRNA. In the cisplatin-sensitive A2780 cells, levels of Shh and Ihh were unchanged after 24 h of anti-Gli1 shRNA. In cisplatin-resistant A2780-CP70 cells, Shh protein was reduced by a factor of five, whereas the Ihh protein level was unchanged. The hedgehog ligands are presumed to activate the Hedgehog pathway at the level of the cell membrane by binding to Patched. 13 --15 As reduction of Gli1 by shRNA also leads to reduction of Shh in these cells, it suggests that in the development of acquired cisplatin resistance, the A2780-CP70 cells developed a feedback loop where Gli1 contributes to the cellular production of Shh ligand. Ihh was unaffected.
Data presented in Figure 1 show that when treated with an IC50 dose of anti-Gli1 shRNA, cisplatin-sensitive A2780 human ovarian cancer cells were not affected with respect to Gli1, Gli2, c-jun, Shh or Ihh. However, there were substantive effects that anti-Gli1 shRNA had on cisplatin-resistant A2780-CP70 cells, with respect to Gli1 and Shh. As discussed above, recent reports indicate that the c-jun gene has Gli binding sites in its 5 0 UTR. We next sought to examine more fully, c-jun mRNA and protein levels, after an IC50 dose of anti-Gli1 shRNA in cisplatin-resistant cells. These results are shown in Figure 2 . We assessed mRNA levels (panel a) and protein levels (panel b) at 6, 24, 48 and 72 h after exposing the cells to an IC50 dose of shRNA. After adjusting for controls, there was neither an increase in expression at 24 h for mRNA nor for protein. Also, there was minimal increase in expression of mRNA and of protein at 48 and 72 h.
When A2780-CP70 cells are treated with an IC50 dose of cisplatin, this results in upregulation of c-jun, with a distinctive phosphorylation pattern. 8, 9, 11 When these same cells are treated with an IC50 dose of anti-Gli1 shRNA, this results in a very different pattern of upregulation of c-jun, and a different phosphorylation pattern of c-jun. These findings are shown in Figure 3 , panels a and b. Panel a shows the pattern with cisplatin, with c-jun peaking at 6 h after treatment, and returning to baseline at 48 h. The phosphorylation of c-jun is at sites Ser63/73, which has been described by others as a pro-growth anti-apoptotic cascade for c-jun. 16 When cells are treated with anti-Gli1 shRNA, the pattern is as shown in panel b. The major c-jun peak is delayed to 48 h with a Thr91/93 phosphorylation peak at 6 --24 h. The Thr91/93 peak has been described as a pro-apoptotic cascade for human cells. 16 The Ser63/73 phosphorylation pattern, shown in panel a, is associated with the upregulation of c-jun. As shown in panel a, when cells are treated with cisplatin only, the levels of Thr91/93 do not change significantly over the 72-h period of observation.
We next examined the effect of anti-Gli1 shRNA on the mRNA and protein levels of selected DNA repair genes in cisplatinresistant A2780-CP70 cells. These results are shown in Figure 4 . In panel a, we examined mRNA levels; and in panel b, protein levels. The genes we assessed were ERCC1, XPD and XRCC1. In these experiments, cells were first treated with shRNA at an IC20 dose for 24 h, then with an IC50 dose of cisplatin for 1 h. When treated with cisplatin alone, ERCC1 would be expected to rise by more than sixfold, 8 as would XPD and XRCC1 (unpublished data). As shown, pretreating the cells with anti-Gli1 shRNA resulted in no observed rise in mRNA or protein over a 72-h period after the cisplatin treatment.
Experiments discussed above indicate that direct inhibition of Gli1 through the use of shRNA results in a block of the upregulation of c-jun and, consequently, ERCC1, XPD and XRCC1. Gli1 is a critical element of the Hedgehog pathway. We therefore asked the question of whether inhibition of the pathway at the level of the cell membrane might have similar effects. We chose to use the classic inhibitor of Smoothened, cyclopamine, 13 to address this question. Figure 5 shows the results of cyclopamine treatment of A2780-CP70 cells on c-jun. Cells were treated at an IC50 dose of cyclopamine, 50 mM. The analysis here is presented in more detail than the analysis of c-jun upregulation in response to anti-Gli1 shRNA, presented above. In this figure, we show nuclear, cytosol and whole-cell lysate, at every time point. As was seen with the use of shRNA, c-jun rose with a substantial delay, compared with cisplatin treatment at the cisplatin IC50 (Figure 3a) . The c-jun rise after cyclopamine treatment was apparent at 24 h and peaked at about 48 h with the predominant phosphorylation pattern at Thr91/93, as was seen with anti-Gli1 shRNA (Figure 3b ). Phosphorylation of c-jun at Ser63 was not observed at any time during the 72-h observation period.
We assessed the upregulation of mRNA of ERCC1, XPD and XRCC1 under the following conditions. A2780-CP70 cells were pretreated with cyclopamine at its IC50 for 24 h, followed by a 1 h exposure to cisplatin at a dose of 30 mM. ERCC1, XPD and XRCC1 showed upregulation of mRNA, to levels approximately twofold over baseline, with the highest levels seen at 24 h after the cisplatin exposure (data not shown). The mRNA peaks were delayed as compared with cisplatin alone, where peak levels occurred at 4 --6 h after the cisplatin exposure. However, this is in contrast to pretreatment with anti-Gli1, where upregulation was blocked for the 72-h period of observation, as shown in Figure 4 .
We next assessed sensitivity to cisplatin, as influenced by antiGli1 shRNA and by cyclopamine. These data are shown in Figure 6 , panel a (shRNA) and panel b (cyclopamine). Optimal supraadditive cell killing was seen with the shRNA, at an IC20 dose of 0.07 mg/well. When cisplatin-resistant A2780-CP70 cells are treated with anti-Gli1 shRNA 24 h before cisplatin, the IC50 is changed from 30 mM with cisplatin alone to 5 mM with the combination. This is a factor of six (panel a). When these cells are pretreated with cyclopamine, the IC50 for cisplatin is not changed (panel b). . RT --PCR mRNA gels (a) and western blots (b) are shown assessing mRNA and protein levels, respectively, for ERCC1, XPD and XRCC1. A2780-CP70 cells were pretreated with anti-Gli1 shRNA, followed by an IC50 dose of cisplatin. Time zero is immediately after the 1 h cisplatin dose. During the 72-h period of observation, there was no substantive increase in the levels of mRNA or protein for any of the three genes assayed. cyclopamine at the IC50 dose of 50 mM. At either dose, the cisplatin cell killing curve was not shifted by cyclopamine. This indicates that inhibition of the Hedgehog pathway at the level of the cell membrane is not associated with a change in cellular sensitivity to cisplatin. However, direct inhibition of Gli1, which is a transcription factor for c-jun, results in altering cellular sensitivity to cisplatin. Concurrently, this is associated with inhibition of the upregulation of three critical DNA repair genes.
When ERCC1 upregulation is blocked in human ovarian cancer cells, repair of platinum --DNA adduct is inhibited. This has been shown using pharmacological agents 9 and using a dominant negative to AP1. 17 Three separate independent experiments were performed to assess the effect of anti-Gli1 shRNA on platinum DNA adduct repair on A2780-CP70 cells. The individual measurements from each experiment of platinum per unit of cellular DNA is shown in Figure 7 , panel a. Cells were pretreated for 24 h with either anti-Gli1 shRNA or scrambled shRNA control. Cells were then treated with cisplatin for 1 h. Cells were harvested immediately, the zero time point, or at 12 h after the cisplatin treatment was completed.
In the scrambled shRNA control, the mean level of platinum --DNA adduct immediately after 1 h of cisplatin, time zero, at a dose of 30 mM, was 4.99 pg pt per mg DNA. The numerical data are given in panel a. After 12 h, the mean level of platinum --DNA adduct in these cells was 1.10 pg pt per mg DNA, or 22% of the baseline level. Therefore, the amount of platinum --DNA adduct repaired at 12 h was 3.90 pg pt per mg DNA. This is fully consistent with previous reports of cisplatin --DNA repair in these cells. 17 --19 In comparison, when the anti-Gli1 shRNA is transfected into cells, the platinum --DNA adduct level immediately after 1 h of cisplatin, time zero, at a dose of 30 mM, was a mean of 4.04 pg pt per mg DNA. After 12 h, the mean level of platinum --DNA adduct in these cells was 2.71 pg pt per mg DNA, or 67% of the baseline level. Therefore, the amount of platinum --DNA adduct repaired at 12 h was 1.33 pg pt per mg DNA. Figure 7 shows three different ways to express the differences between anti-Gli1 shRNA, and scrambled shRNA control, in terms of the repair of platinum --DNA adduct in A2780-CP70 cells. In panel b, we show that in control cells, DNA adducts levels are reduced from 100% of baseline to 22% of baseline over 12 h, or 78% repair. In panel b, under the influence of anti-Gli1 shRNA, DNA adduct levels are reduced from 100% of baseline to 67% of baseline, or 33% repair. Figure 7 panel c, shows the differences between anti-Gli1 shRNA and scrambled control in terms of absolute platinum levels measured at the two time points studied. In scrambled control cells, mean DNA adduct levels were reduced from 4.99 units to 1.10 units. In cells pretreated with anti-Gli1 shRNA, adduct levels were reduced from 4.04 units to 2.71 units. The detailed numbers are given in panel a. Figure 7 panel d, data are plotted as the absolute amounts of platinum removed, under the two different experimental conditions, anti-Gli1 shRNA and scrambled control. In control cells, 3.90 units of adduct were removed over 12 h, whereas in cells treated with anti-Gli1 shRNA, 1.33 units of adduct were removed over 12 h. This is a factor of three.
In Figure 7 panel a, we compared the percent repair of control cells to that observed in cells treated with anti-Gli1 shRNA for each independent experiment. The percent of baseline DNA damage in control cells in each of the three experiments was: 17% in the first, 14% in the second and 49% in the third, for a mean of 26.7%. The analogous number in cells treated with anti-Gli1 shRNA was: 88% in the first, 51% in the second and 82% in the third, for a mean of 73.7%. These numbers are statistically different with a two-sided P-value of 0.04.
DISCUSSION
In this manuscript, we show that anti-Gli1 shRNA transfection into cisplatin-resistant A2780-CP70 human ovarian cancer cells results in a series of specific events. The c-jun protein cascade is switched from a Ser63/73 cascade to a Thr91/93 cascade. Cisplatin induction of ERCC1 is blocked along with the induction of XPA and XRCC1. Repair of platinum --DNA adduct is reduced by 460%; and the cells become more sensitive to cisplatin by a factor of six, with a change in the IC50 from 30 mM to 5 mM. Further, when Hedgehog is inhibited at the level of the cell membrane, cellular sensitivity is not altered. This distinction may prove quite important in the development of pharmacological treatment strategies for cancer, where cisplatin resistance is a substantive clinical issue.
It is noteworthy that in cisplatin-resistant cells, treatment with the anti-Gli1 shRNA eliminated Gli1 message and Shh message (Figure 1 ). This did not occur in cisplatin-sensitive parental A2780 cells. This suggests that the development of cisplatin resistance may be related to the development of a feedback loop between the positive transcription factor, Gli1, and an external stimulus that activates the pathway, sonic hedgehog ligand. It is possible that elucidation of the relationship may yield important insights into the development of cisplatin resistance in human ovarian cancer.
The Hedgehog pathway is of critical importance in early fetal development, 20, 21 in maintenance of the cancer stem cell, 22, 23 and of critical clinical importance in several important malignancies. 24 --26 Its role in cancer stem cell biology is not clear, but may be related in part to the extreme drug resistance phenotype of cancer stem cells. The data we present suggest that Gli1 may be important in the transcriptional regulation of at least one gene that is critical to the transcriptional control of ERCC1, XPD, and NER. Also, the data suggest a role for Gli1 in the control of XRCC1 and base excision repair.
ERCC1 is necessary for the repair of cisplatin --DNA adduct. ERCC1 mRNA levels and protein levels in tumor tissues are directly related to clinical resistance to platinum-based chemotherapy. Studies in a range of cancers have shown that levels of ERCC1 mRNA and/or ERCC1 protein are directly related to clinical resistance to platinum-based chemotherapy for: ovarian cancer, 27 40 and in every living organism yet examined. Coordinate expression of genes involved in the NER repairosome has been observed in: non-malignant bone marrow, 41 brain cancer, 42, 43 and ovarian cancer. 44, 45 The upregulation of ERCC1 is accompanied by concurrent upregulation of other critically important genes of the NER repairosome in human cells and tissues. These genes include: XPA, XPB, XPD and CSB. All of these genes have AP1 binding sites in their promoter regions. 46 AP1 is the heterodimer of c-jun and c-fos. As Gli1 participates in the transcription of c-jun, Gli1 may have a role in the regulation of other genes in the NER repairosome that are influenced by c-jun.
The specific c-jun phosphorylation pattern that is associated with the formation of activator protein 1 is the Ser63/73 pattern. 8 Blockage of the formation of AP1, either through inhibition of c-jun or c-fos, results in blockage of upregulation of ERCC1 and inhibition of platinum --DNA adduct repair. 8, 9, 17 The Ser63/73 upregulation cascade is non-overlapping with the Thr91/93 upregulation cascade. These two cascades appear to regulate different intracellular processes. 16 The Ser63/73 cascade is associated with upregulation of a number of pro-survival genes. 16 In contrast, the Thr91/93 cascade may be more pro-apoptotic; and is modulated by the phosphorylation of Thr95 before the phosphorylation of Thr91/93. 16 The upregulation of c-jun may occur in response to a number of disparate agents. 16 As AP 1 is important in a number of cellular processes, the influence of AP1 may not be limited to DNA repair. Also, as Gli1 is important to a number of intracellular processes, it is anticipated that the inhibition of Gli1 may result in inhibition of DNA repair and additional intracellular pathways. These questions are the focus of ongoing studies in our laboratory. However, the fundamental findings we present in this manuscript are illustrated in Figure 8 . Gli1 controls c-jun, and c-jun controls ERCC1 and other DNA repair genes (Figure 8a ). When Gli1 is inhibited, the resultant molecular events lead to the blockage of ERCC1 (Figure 8b ). Gli1, c-jun and ERCC1 K Kudo et al
MATERIALS AND METHODS

Cell lines used
Cisplatin-sensitive A2780 human ovarian cancer cells and cisplatinresistant A2780-CP70 human ovarian cancer cells have been studied extensively by this laboratory. 8 --11 Cells were retrieved from frozen stock and were used in these studies between passages 5 and 30. RPMI 1630 media (Gibco, Carlsbad, CA, USA) was used with the following additives; 10% fetal bovine serum (Gibco), L-glutamine (Gibco), insulin (SigmaAldrich, St Louis, MO, USA) and penicillin/streptomycin (Gibco). Cisplatin was purchased from Sigma-Aldrich, and dissolved in normal saline at 1 mg/ ml before further dilution into complete media. For cell killing assays, WST-1 was purchased from Roche Applied Science, Indianapolis, IN, USA.
Western blot experiments for Gli1, Gli2, Shh and Ihh Cells were seeded onto six-well plates at 500 000 cells/well overnight. After growth medium was changed with new medium, cells were transfected with anti-Gli1 construct (shRNA) or scramble control 47 using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After transfection for 24, 48 and 72 h, cells were scraped and lysed for western blotting. Total cell extracts were prepared by lysing cells in radio-immunoprecipitation assay lysis buffer, and protein levels in cytosolic and nuclear fractions were also detected. Controls were treated with Lipofectamine only.
Equal amount of proteins were resolved by SDS --PAGE on 6% gels by the method of Laemmli and transferred to polyvinylidene fluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were then blocked by 1% nonfat milk in TBS-0.5% Tween 20 at room temperature for 1 h. We obtained the following antibodies from Cell Signaling (Danvers, MA, USA): c-jun, p-c-jun(Ser63), p-c-jun(Ser73), c-fos, HDAC3, GAPDH and Gli1. We obtained the following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA): alpha-tubulin, Gli2, Shh and Ihh. The antibody to p-c-jun(Thr91/93) was obtained from Abcam (Cambridge, MA, USA). Horseradish peroxidase-conjugated antibodies against mouse (1:5000; Santa Cruz) or rabbit (1:2000; Cell Signaling) were used as secondary antibodies. Protein bands were visualized with a chemiluminescence detection system using the Super Signal West Dura Extended Duration substrate (Thermo Pierce, Rockford, IL, USA).
Cell survival assays
Cells were seeded onto 96-well plates at 6000 cells/dish overnight. After growth medium was changed with new medium, cells were treated with the respective agent. In one set of experiments, cells were transfected with anti-Gli1 construct (shRNA) using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions. Cells were then treated with cisplatin (Sigma) at the respective dose, þ /Àtransfection. After incubating with the drugs for 24, 48 and 72 h, the medium was removed and 10% WST-1 (WST-1 in growth medium, Roche, Madison, WI, USA) was added to each well. After incubation with WST-1 for 1 h, absorbance was measured with Gen5 plate reader (BioTeK, Winooski, VT, USA). Lipofectamine2000 was added to control wells, at the same time as drug treated wells. In a separate set of experiments, cells were treated with cyclopamine instead of anti-Gli1 shRNA.
RT --PCR method
Total RNA was isolated from cells by using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Quantitative real-time PCR (qRT--PCR) to measure gene-specific mRNA levels was performed on a BioRad iQ5 real-time PCR detection system. cDNAs were synthesized with a High-Capacity cDNA Synthesis kit (Applied Biosystems, Carlsbad, CA, USA) using random primers and 2 mg of total RNA as the template, and qRT--PCR performed using specific primers and probes for the following genes: c-Jun, ERCC1, XPD, XRCC1 and GAPDH (internal control). The following conditions were used for all reactions: reverse transcription at 50 1C for 10 min with denaturing at 95 1C for 10 min followed by o30 PCR cycles, 95 1C for 15 s and 60 1C for 1 min. All primers and probes were obtained from Applied Biosystems. The probes and product numbers are as follows: ERCC1, Hs01012158_m1; XPD, Hs00361161_m1; XRCC1, Hs00959834_m1; GAPDH, Hs99999905_m1; Gli1, Hs01110776_g1; fos, Hs01119267_g1; and jun, Hs99999141_s1.
Atomic absorbance spectrometry measurement of platinum --DNA adduct repair A2780-CP70 cells were grown in complete media as described above, and were treated with anti-Gli1 shRNA, or a scrambled variant of the same base content and same length. 47 Fugene (Roche) was used as the transfection agent. Cells were plated on day 1, shRNA transfection was performed on day 2, and cisplatin treatment was performed 24 h after shRNA transfection. Cisplatin dose was 30 mM for 1 h; the Fugene concentration was 60 ml per 20 mg DNA plasmid. Cells were treated with cisplatin at 80 --90% confluence.
Cells were harvested after cisplatin dosing. Time zero was immediately after the 1 h cisplatin dose. Cells were also harvested 12 h later. Based on previous studies, this 12-h period completely encompasses the rapid phase of repair of platinum --DNA adduct. 8, 18, 19 Nuclear DNA was isolated from cells using Qiagen blood and cell culture DNA midi kit (Qiagen, Gaithersburg, MD, USA). After precipitation, DNA was resuspended in double-distilled H 2 O, sonicated and quantitated by ultraviolet absorbance at 260 nm.
Atomic absorbance spectrometry was used to assay for total platinum in each DNA sample. A Perkin-Elmer 600 AAnalyst machine was used with Zeeman background correction (Perkin-Elmer, Walthan, MA, USA). A Perkin-Elmer platinum lamp and Perkin-Elmer cisplatin standard were also used. Settings for platinum measurement by atomic absorbance spectrometry have been previously described. 18, 48 Total platinum per milligram of cellular DNA was determined based on DNA content and total platinum content of each specimen assayed. The amount of platinum in cellular DNA at zero hours was compared with total platinum in cellular DNA at 12 h. The difference in levels of platinum --DNA damage at these two time points was assessed as total platinum removed from cellular DNA over the 12 h of observation.
